Combined Fmoc-Alloc strategy for a general SPPS of phosphoserine peptides; Preparation of phosphorylation-dependent Tau antisera

Bioorganic and Medicinal Chemistry

Volumn 5, Issue 1, 1997, Pages 147-156

  Shapiro, Gideon ^a   Büchler, Dieter ^c   Dalvit, Claudio ^c   Frey, Peter ^b   Del Carmen Fernández, Maria ^c   Gomez Lor, Berta ^c   Pombo Villar, Esteban ^c   Stauss, Urs ^b   Swoboda, Robert ^b   Waridel, Caroline ^b  

^a Preclinical Research   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

^c NONE

Author keywords

Alloc; Alzheimer's Disease; Solid phase phosphopeptide synthesis; Tau antisera; Tau phosphopeptide

Indexed keywords

PHOSPHOPEPTIDE; PROTEIN ANTIBODY; TAU PROTEIN; TAU PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTIBODY PRODUCTION; CONFERENCE PAPER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PEPTIDE SYNTHESIS; PROTEIN STRUCTURE; REACTION ANALYSIS; TECHNIQUE;

AMINO ACID SEQUENCE; ANTIBODY FORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; IMMUNE SERA; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR SEQUENCE DATA; PHOSPHOPEPTIDES; PHOSPHORYLATION; SERINE; SPECTROMETRY, MASS, FAST ATOM BOMBARDMENT; TAU PROTEINS;

EID: 0031021348     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(96)00211-8     Document Type: Conference Paper

References (45)

1. 1. (a) Perich, J. W. In Peptides and Protein Phosphorylation; Kemp, B. E. Ed.; CRC Press: Boca Raton, 1990;
2. (b) de Bont, D. B. A.; Moree, W. J.; Van Boom, J. H.; Liskamp, R. M. J. Org. Chem. 1993, 58, 1309;
3. (c) Frank, A. W. CRC Crit Rev. Biochem. 1984, 16, 51.
4. 2. (a) Enz, A.; Shapiro, G.; Chapuis, A.; Dattler, A. Analyt. Biochem., 1994, 216, 147;
5. (b) Donnella-Deanna, A.; Krinks, M. H.; Ruzzene, M.; Klee, C.; Pinna, L. Eur. J. Biochem. 1994, 219, 109.
6. 3. (a) Shapiro, G.; Swoboda, R.; Stauss, U. Tetrahedron Lett. 1994, 55, 869;
7. (b) Andrews, D, M.; Kitchin, J.; Seale, P. W. Int. J. Peptide Protein Res. 1991, 38, 469.
8. 4. Atherton, E.; Sheppard, R. C. Solid Phase Peptide Synthesis; Richwood, D.; Hamas, B. D. Eds.; The Practical Approach Series; Information Press Ltd.: Oxford, 1989.
9. 0 catalysed cleavage protocolls. For a recent list of citations see reference 12(b).
10. 6. A simple, novel pivaloylchloride-dibenzylphosphite mediated phosphitylation procedure for the synthesis of phosphopeptides has been described as alternative to oxidatively and hydrolytically unstable phosphoramidates: Lüning, B.; Larsson, E. Tetrahedron Lett. 1994, 35, 2737.
11. 3b and may require careful selection of experimental conditions. Ötvos, L.; Elekes, I.; Lee, Int. J. Peptide Protein Res. 1989, 34, 129.
12. 8. Stewart, J. M.; Young, J. D. Solid Phase Peptide Synthesis; Pierce Chemical Co.: Rockford, Illinois, 1984.
13. 9. A preliminary communication of this method has been published: Shapiro, G.; Büchler, D.; Dalvit, C.; Fernandez, M.; Gomez-Lor, B.; Pombo-Villar, E.; Stauss, U.; Swoboda, R. Bioorg. Med. Chem. Lett. 1996, 6, 409.
14. 10. (a) Kunz, H.; Unverzagt, C. Angew. Chem. Int. Ed. Engl. 1984, 23, 436;
15. (b) Kunz, H.; Waldmann, H. Angew. Chem. Int. Ed. Engl. 1984, 23, 71.
16. 11. Biernat, J.; Gustke, N.; Drewes, G.; Mandelkow, E. M.; Mandelkov, E. Neuron 1993, 11, 153.
17. 12. (a) Tsukamoto, M.; Kato, R.; Ishguro, K.; Uchida, T.; Sato, K. Tetrahedron Lett. 1991, 32, 7083. Very recently other Boc-SPPS of serine phosphopetides have appeared;
18. (b) Ueno, Y.; Suda, F.; Taya, Y.; Noyori, R.; Hayakawa, Y.; Hata, T. Bioorg. Med. Chem. Lett. 1995, 5, 823;
19. (c) Otaka, A.; Miyoshi, K.; Roller, P. R.; Burke; T.; Tamamura, H.; Fujii, N. J. Chem. Soc. Chem. Comm. 1995, 387.
20. 13. Lacombe, J. M.; Andriamanampisoa, F.; Pavia, A. A. Int. J. Peptide Protein Res. 1990, 36, 275.
21. 14. Shapiro, G.; Büchler, D. Tetrahedron Lett. 1994, 35, 5421. This method is particularly intended for solid phase applications where the allyl azide formed may simply and safely be disposed of in dilute solution. Extreme caution should be exercised in applying the method to standard solution phase chemistry.
22. 15. Use of either the method described in 3a or 3b resulted in insignificant if any phosphorylation product (1) but a good yield of the unphosphorylated material.
23. 16. Kitas, E. A.; Knorr, R.; Trzeciak, A.; Bannwarth, W. Helv. Chim. Acta 1991, 74, 1314.
24. 17. The chromatographic purification of 6 prepared as above is an absolute requirement whereas crude material received from the clean last step as described in ref 9 is of sufficient purity to use directly or convert to the DCHA salt.
25. 18. Knorr, R.; Trzeciak, A.; Bannwarth, W.; Gillessen Tetrahedron Lett. 1989, 30, 1927.
26. 2)-Thr-Glu-Asn-Leu-Lys-His -OH was formed cleanly.
27. 20. Mergler, M.; Tanner, R.; Gosteli, J.; Grogg, P. Tetrahedron Lett. 1988, 29, 4005.
28. 21. Piotto, M.; Saudek, V.; Sklenar, V. J. Biomol. NMR 1992, 2, 661.
29. 22. Summers, M. F.; Marzilli, L. G.; Bax, A. J. Am. Chem. Soc. 1986, 108, 4285.
30. 23. Harding, S. J.; Heslop, I.; Jones, J. H.; Wood, M. E. Proceedings of the 23rd European Peptide Symposium ed. Maia, H.L.S. ed., ESCOM: Leiden, 1995; pp 189-190.
31. 24. Sieber, P. Tetrahedron Lett. 1987, 28, 6147.
32. 3a
33. 26. For other examples of such phosphorylation dependent tau antisera see: (a) Liu, W.-K.; Moore, W, T.; Williams, R. T.; Hall, F. L.; Yen, S.-H. J. Neurosci. Res. 1993, 34, 371;
34. (b) Liu, W.-K.; Yen, S.-H. J. Neurochem. 1996, 66, 1131;
35. (c) Ishiguro, K.; Sato K.; Takamatsu, M.; Park, J.; Tsuneko, U.; Imahori, K.; Neurosci. Lett. 1995, 202, 81;
36. (d) Seubert, P., Mawal-Dewan, M.; Barbour, R.; Jakes, R.; Goedert, M.; Johnson, G. V. W.; Literski, J. M.; Schenk, D.; Lieberburg, I.; Trojanowski, J. Q.; Lee, V. M.-Y. J. Biol. Chem. 1995, 270, 18917.
37. 27. Goedert, M.; Spillantini, M. G.; Jakes, R.; Crowther, R. A.; Vanmechelen, E.; Probst, A.; Götz, J.; Bürki, K.; Cohen, P. Neurobiol. Aging 1995, 16, 325.
38. 28. Wakamiya, T.; Saruta, K.; Yasuoka, J.; Kusumoto, S. Chem. Lett. 1994, 1099.
39. 29. Vorherr, T.; Bannwarth, W. Bioorg. Med. Chem. Lett. 1995, 5 2661.
40. 30. The major side product depicted in the HPLC profile using compound 4 in reference 28 has been determined to be the corresponding pyrophosphate dimer the phosphopeptide. Wakamiya et al., Poster at the 23rd European Peptide Symposium (not reported in proceedings).
41. 31. The Roche group has also reported the compatibility of 3 with automated Fmoc synthesis using HBTU. We used the Applied Biosystems ABI430A peptide synthesizer using the Fast-Moc cycles routine which employs HBTU as an activator and large (7X) excesses in the coupling step to achieve more rapid Fmoc synthesis.
42. 32. Amino acid 3 can be purchased from Novabiochem, Switzerland.
43. 33. Medzihradszky, D.; Chen, S. L.; Kenyon, G. L.; Gibson, B. J. Am. Chem. Soc. 1994, 116, 9413.
44. 34. Dalvit, C.; Bovermann G. Magn. Reson. Chem, 1995, 33, 156.
45. 35. Goedert, M.; Jakes, R.; Crowther, R. A.; Six, J.; Luebke, U.; Vandermeeren, M.; Cras, P.; Trojanowski, J. Q.; Lee, V. M. Y. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 5066.